Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia

References

• Tesfaye DY, Kinde S, Medhin G, et al. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia. Diabetes Metab Syndr. 2014;8(2):102–107. doi:10.1016/j.dsx.2014.04.008
   PubMedGoogle Scholar
• Altizani G, de Oliveira L, Dos Santos Tortajada J, Monteleone V, Bonafe S. Management of cardiovascular and metabolic alterations in HIV positive patients. Int J AIDS Res. 2016;3(7):105–113.
   Google Scholar
• Fontas E, Van Leth F, Sabin C, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189(6):1056–1074. doi:10.1086/381783
   PubMed Web of Science ®Google Scholar
• Gatell J, Ceron DS, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44(11):1484–1492. doi:10.1086/517497
   PubMed Web of Science ®Google Scholar
• Achenbach CJ, Darin KM, Murphy RL, Katlama C. Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol. 2011;6(2):157–177. doi:10.2217/fvl.10.89
   Web of Science ®Google Scholar
• Havlir DV, O’marro SD. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004;38(11):1599–1604. doi:10.1086/420932
   Web of Science ®Google Scholar
• Ulrike M, Margrit L-R, Brigitte C-F, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J AIDS. 2005;39(2):1–7.
   Web of Science ®Google Scholar
• Giuntini R, Martinelli C, Ricci E, et al. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med. 2010;11:40–45. doi:10.1111/j.1468-1293.2009.00740.x
   PubMed Web of Science ®Google Scholar
• Pereira SA, Branco T, Côrte‐Real RM, et al. Long‐term and concentration‐dependent beneficial effect of efavirenz on HDL‐cholesterol in HIV‐infected patients. Br J Clin Pharmacol. 2006;61(5):601–604. doi:10.1111/j.1365-2125.2006.02619.x
   Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Collier AC. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann Intern Med. 2011;154:445–456. doi:10.7326/0003-4819-154-7-201104050-00316
   PubMed Web of Science ®Google Scholar
• Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42:273–280. doi:10.1086/498505
   PubMed Web of Science ®Google Scholar
• Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36(5):1011–1019. doi:10.1097/00126334-200408150-00003
   PubMed Web of Science ®Google Scholar
• Ganesan A, Benning L, Golub ET, et al. Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens. AIDS Res and Therapy. 2009;6(13):1–7. doi:10.1186/1742-6405-6-13
   Google Scholar
• Gotti D, Cesana BM, Albini L, et al. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir. HIV Clin Trials. 2012;13(5):245–255. doi:10.1310/hct1305-245
   PubMed Web of Science ®Google Scholar
• Sension M, Deckx H. Lipid metabolism and lipodystrophy in HIV-1 infected patients: the role played by nonnucleoside reverse transcriptase inhibitors. AIDS Rev. 2015;17:21–36.
   Web of Science ®Google Scholar
• Chow D, Shikuma C, Ritchings C, Guo M, Rosenblatt L. Atazanavir and cardiovascular risk among human immunodeficiency virus-infected patients: a systematic review. Infect Dis Ther. 2016;5:473–489. doi:10.1007/s40121-016-0132-z
   PubMed Web of Science ®Google Scholar
• Husain NEO, Ahmed MH. Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. HIV/AIDS – Res Palliative Care. 2015;7:1–10.
   Google Scholar
• Organization WH. Obesity: Preventing and Managing the Global Epidemic. World Health Organization; 2000.
   Google Scholar
• Organization WH. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008. 2011.
   Google Scholar
• El Hadri K, Glorian M, Monsempes C, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem. 2004;279(15):15130–15141. doi:10.1074/jbc.M312875200
   Web of Science ®Google Scholar
• Tarr PE, Taffé P, Bleiber G, et al. Modeling the influence of APOC3, APOE and TNF polymorphisms on the risk of antiretroviral therapy–associated lipid disorders. J Infect Dis. 2005;191(9):1419–1426. doi:10.1086/429295
   Web of Science ®Google Scholar
• Flint O, Bellamine A, Noor M, van der Hoorn J, Princen H, Parker R. Effects of efavirenz on lipid metabolism in APOE* 3* Leiden hCETP double-transgenic mice: evidence for antagonism of LXR pathway. Antivir Ther. 2007;12:L5.
   Web of Science ®Google Scholar
• Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995;333(23):1528–1534. doi:10.1056/NEJM199512073332303
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Andrade‐Villanueva J, Clotet B, et al. Lipid profiles for nevirapine vs atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN Study). HIV Med. 2011;12(6):374–382.
   PubMed Web of Science ®Google Scholar
• Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol. 2014;13(1):146. doi:10.1186/s12933-014-0146-3
   PubMed Web of Science ®Google Scholar
• Iwani NAKZ, Jalaludin MY, Zin RMWM, et al. Triglyceride to HDL-C ratio is associated with insulin resistance in overweight and obese children. Sci Rep. 2017;7(1):1–7. doi:10.1038/srep40055
   Web of Science ®Google Scholar
• Knight MG, Goedecke JH, Ricks M, et al. The TG/HDL-C ratio does not predict insulin resistance in overweight women of African descent: a study of South African, African American and West African women. Ethn Dis. 2011;21(4):490.
   Web of Science ®Google Scholar
• Sumner AE, Zhou J, Doumatey A, et al. Low HDL-cholesterol with normal triglyceride levels is the most common lipid pattern in West Africans and African Americans with metabolic syndrome: implications for cardiovascular disease prevention. CVD Prev Control. 2010;5(3):75–80. doi:10.1016/j.cvdpc.2010.07.003
   Google Scholar
• Millán J, Pintó X, Muñoz A, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757.
   PubMedGoogle Scholar
• Belay E, Seifu D, Amogne W, Kibret K. Lipid profile derangements among human immunodeficiency virus infected adults receiving first line anti-retroviral therapy in Tikur Anbesa specialized hospital, Addis Ababa, Ethiopia: comparative cross-sectional study. J AIDS Clin Res. 2014;5:328.
   Google Scholar
• Kamoru A, Japhet O, Adetunji A, et al. CD4+ cell count, lipid and lipoprotein levels in HIV patients on drug treatment. Int J AIDS Res. 2017;4:140–146.
   Google Scholar
• Amberbir A, Singano V, Matengeni A, et al. Dyslipidemia among rural and urban HIV patients in south-east Malawi. PLoS One. 2018;13(5). doi:10.1371/journal.pone.0197728
   Web of Science ®Google Scholar
• Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169(6):572–578. doi:10.1001/archinternmed.2008.599
   PubMedGoogle Scholar
• Mendicino CCP, Braga LP, CAMd P, Guimarães MDC. High incidence of hypertriglyceridemia in a Brazilian cohort of people living with HIV/AIDS undergoing antiretroviral treatment in Belo Horizonte, 2001–2010. Rev Soc Bras Med Trop. 2016;49(6):758–762. doi:10.1590/0037-8682-0078-2016
   Web of Science ®Google Scholar
• Armstrong C, Liu E, Okuma J, et al. Dyslipidemia in an HIV-positive antiretroviral treatment-naive population in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr. 2011;57:141–145. doi:10.1097/QAI.0b013e318219a3d1
   Web of Science ®Google Scholar